Micafungine Reig Jofre

Micafungin, the active ingredient in Micafungine Reig Jofre, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive Candida infections, including bloodstream and esophageal disease, and is used for prophylaxis in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungine Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology clinics worldwide with consistent quality and regulatory compliance.

Micafungin is indicated for several invasive Candida infections and for prophylaxis in high‑risk patients.

Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections. Esophageal candidiasis: eradication of Candida infection of the esophagus. Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevention of invasive candidiasis in transplant recipients.

Micafungine Reig Jofre may cause a range of adverse reactions.

Common Side Effects: - Elevated liver enzymes (ALT, AST) - Fever or chills during infusion - Nausea or vomiting - Headache

Serious or Rare Side Effects: - Hypersensitivity reactions, including anaphylaxis - Severe hepatic dysfunction or jaundice - Acute renal impairment or increased creatinine - Severe infusion‑related reactions such as hypotension or bronchospasm

Use of Micafungine Reig Jofre requires careful clinical monitoring.

Renal function: monitor serum creatinine and adjust therapy if impairment occurs. Hepatic function: assess liver enzymes before initiation and periodically during treatment. Drug interactions: review concomitant medications for potential CYP‑mediated effects. Pregnancy and lactation: prescribe only when benefits outweigh potential risks; safety data are limited. Patient monitoring: observe for signs of hypersensitivity during and after infusion. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine Reig Jofre can interact with several agents; clinical judgment is required.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure; avoid co‑administration. - Rifampin: markedly reduces micafungin plasma levels; avoid. - Concurrent azole antifungals (e.g., fluconazole): may increase toxicity; avoid.

Moderate Interactions (Monitor Closely): - Carbapenems (e.g., meropenem): may affect micafungin clearance; monitor levels. - Immunosuppressants (e.g., tacrolimus): possible increased concentrations; monitor. - Statins: potential for increased risk of myopathy; monitor muscle symptoms.